Related Experiment Video
Updated: May 3, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
2.2K
How does brain insulin resistance develop in Alzheimer's disease?
Fernanda G De Felice1, Mychael V Lourenco1, Sergio T Ferreira1
1Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|February 18, 2014
Summary
Alzheimer's disease (AD) and diabetes share common pathways involving insulin resistance. Understanding brain insulin dysfunction offers new therapeutic targets for AD.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Pathophysiology
Background:
- Alzheimer's disease (AD) and diabetes exhibit shared pathological features, including altered metabolism, inflammation, and insulin resistance.
- The brain's sensitivity to insulin and its role in cognitive functions like learning and memory, which are impaired in AD, are increasingly recognized.
- Molecular mechanisms underlying brain insulin resistance in AD have been a significant research gap.
Purpose of the Study:
- To review recent evidence elucidating the molecular initiation of brain insulin dysfunction in Alzheimer's disease.
- To explain how aberrant insulin signaling leads to synaptic failure and memory decline.
- To discuss the cellular basis for cognitive benefits derived from stimulating brain insulin signaling.
Main Methods:
- Review of preclinical and clinical evidence.
- Analysis of molecular and cellular mechanisms.
- Synthesis of current research on brain insulin signaling in AD.
Main Results:
- Evidence supports a pathophysiological link between AD and diabetes via insulin resistance.
- Molecular mechanisms of brain insulin resistance in AD are being uncovered.
- Stimulation of brain insulin signaling shows potential for cognitive benefits.
Conclusions:
- Understanding brain insulin dysfunction is crucial for AD pathophysiology.
- Novel molecular targets for AD therapeutics can be identified through this research.
- This work provides a foundation for developing alternative therapeutic strategies for AD.
More Related Videos
08:34Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
Published on: July 15, 2025
734
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
11.7K
Related Concept Videos
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:24Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:26Type I Diabetes II: Pathophysiology
75
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35